Aschenbrenner, Andrew JBaksh, R AsaadBenejam, BessyBeresford-Webb, Jessica ACoppus, AntoniaFortea, JuanHanden, Benjamin LHartley, SiganHead, ElizabethJaeger, JudithLevin, JohannesLoosli, Sandra VRebillat, Anne-SophieSacco, SilviaSchmitt, Frederick AThurlow, Kate EZaman, ShahidHassenstab, JasonStrydom, Andre
The Down syndrome population faces early onset Alzheimer’s disease at a rate much higher than the general population. More research is needed to develop ways to assess the efficacy of prevention trials that target DS. Through this work, researchers have identified a composite assessment that can highlight early decline.Thus, this composite may be used as an outcome measure in trials to prevent or delay symptoms of AD in DS.
Down syndrome (DS), a genetic variant of early onset Alzheimer's disease (AD), lacks a suitable outcome measure for prevention trials targeting pre-dementia stages. We used cognitive test data collected in several longitudinal aging studies internationally from 312 participants with DS without dementia to identify composites that were sensitive to change over time. We then conducted additional analyses to provide support for the utility of the composites. The composites were presented to an expert panel to determine the most optimal cognitive battery based on predetermined criteria. There were common cognitive domains across site composites, which were sensitive to early decline. The final composite consisted of memory, language/executive functioning, selective attention, orientation, and praxis tests. We have identified a composite that is sensitive to early decline and thus may have utility as an outcome measure in trials to prevent or delay symptoms of AD in DS.
Alzheimer Disease, Alzheimer Disease, Early Onset, Cognitive Decline, Dementia